Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy

J Infect Dis. 2021 Feb 15;223(12 Suppl 2):38-45. doi: 10.1093/infdis/jiaa223.

Abstract

HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.

Keywords: T-cell exhaustion; T-cell receptor; antiretroviral therapy; chimeric antigen receptor; ex vivo T-cell expansion; human-immunodeficiency-virus; latency reversing agent.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adaptive Immunity
  • Adoptive Transfer*
  • Animals
  • CD4-Positive T-Lymphocytes / immunology*
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV Infections / virology
  • HIV-1 / genetics
  • HIV-1 / physiology*
  • Humans